Sage Sues Partner Biogen After Unsolicited Takeover Offer
Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by …
Sage sues Biogen after unsolicited takeover bid | pharmaphorum
3 days ago · Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal.
Sage seeks injunction after Biogen's unsolicited buyout offer
Jan 21, 2025 · Biogen’s offer, at about $469 million, effectively assigns Sage a negative value because the Massachusetts biotech had about $569 million in cash and equivalents at the end …
Sage rejects Biogen's $469 million takeover offer, says offer ...
Jan 27, 2025 · Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. Shares of Sage were up …
Sage rejects Biogen’s $469m takeover bid - Yahoo Finance
Jan 28, 2025 · Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the company. Made …
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding ...
Jan 10, 2025 · No Shareholder Action Required at This Time. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2025-- Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today …
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Jan 28, 2025 · BIIB's Recent Offer to Acquire SAGE. Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 …
Sage rejects Biogen’s buyout offer, but says it's open to deals
Jan 27, 2025 · Sage Therapeutics Inc. is looking for a deal — but it’s not interested in the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.. …
Sage Therapeutics and Biogen Announce Topline Results from …
CAMBRIDGE Mass. – July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of …
Biogen and Sage Therapeutics Announce FDA Accepts Filing of …
CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration …
- Some results have been removed